证券代码：300436 证券简称：广生堂 公告编号：2025036 福建广生堂药业股份有限公司 福建广生堂药业股份有限公司（以下简称"公司"）第五届董事会第九次会 议于 2025 年 4 月 21 日以邮件、电话等形式发出通知，于 2025 年 4 月 24 日以通 讯表决方式召开。会议由董事长李国平先生主持，会议应出席董事 8 人，实际出 席董事 8 人，监事会成员列席了会议。会议的召开符合《公司法》和《公司章程》 的规定。 二、董事会会议审议情况 （一）审议通过《关于<2025年第一季度报告>的议案》 经审核，董事会认为公司《2025 年第一季度报告》的编制程序符合法律、行 政法规的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任 何虚假记载、误导性陈述或者重大遗漏。 表决结果：有效表决票数8票，同意8票，反对0票，弃权0票。 本议案已经公司第五届董事会审计委员会审议通过。 关于第五届董事会第九次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 福建广生堂药业股份有限公司董事会 2025 年 4 月 24 ...

广生堂（300436）公告，2025年第一季度营业收入9760.8万元，同比下降18.69%。净亏损2848.89万 元，去年同期净亏损1464.27万元。 ...

前十大流通股东累计持有： 5830.32万股，累计占流通股比： 42.65%，较上期变化： -104.53万股。 | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 福建奥华集团有限公司 | 2706.87 | 19.80 | -800.00 | | 福建平潭奥泰科技投资中心(有限合伙) | 802.50 | 5.87 | 不变 | | 漳州战新创业投资基金管理有限公司-漳州圆山大健康产业 | | | | | 投资基金合伙企业(有限合伙) | 800.00 | 5.85 | 新进 | | 叶理青 | 338.42 | 2.48 | 不变 | | 中信建投（601066）医改A | 230.00 | 1.68 | 不变 | | 李国平 | 225.02 | 1.65 | 不变 | | 蔡云霞 | 216.05 | 1.58 | 1.00 | | 李国栋 | 187.50 | 1.37 | 不变 | | 黄彩艳 | 178.80 | 1.31 | 不变 | | 中欧医疗健康混合A | 145.16 | 1 ...

Financial Performance - The company's revenue for Q1 2025 was ¥97,607,995.93, a decrease of 18.69% compared to ¥120,047,604.86 in the same period last year[4] - The net loss attributable to shareholders was ¥28,488,936.37, representing a 94.56% increase in losses from ¥14,642,717.07 year-on-year[4] - The basic earnings per share were -¥0.1789, a decline of 94.67% compared to -¥0.0919 in the previous year[4] - Net loss for the period was ¥29,523,406.44, compared to a net loss of ¥14,706,929.43 in the previous period, indicating a significant increase in losses[19] - The total comprehensive loss for the period was ¥29,523,406.44, compared to a comprehensive loss of ¥14,706,929.43 in the previous period[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,383,018,070.86, down 3.88% from ¥1,438,807,956.07 at the end of the previous year[4] - The company's total assets decreased to ¥1,383,018,070.86 from ¥1,438,807,956.07, a decline of approximately 3.9%[17] - Total liabilities decreased to ¥1,015,763,555.73 from ¥1,042,030,034.50, a reduction of about 2.5%[17] - The equity attributable to the parent company decreased to ¥331,689,887.35 from ¥360,178,823.72, a decline of approximately 7.9%[17] Cash Flow - The net cash flow from operating activities was -¥12,553,020.77, showing a slight improvement of 5.05% from -¥13,220,727.89 year-on-year[4] - Operating cash inflow totaled $116,544,042.68, down from $133,553,914.09 in the previous period, representing a decrease of approximately 12.7%[21] - Cash outflow from operating activities was $129,097,063.45, compared to $146,774,641.98 in the prior period, indicating a reduction of about 12.1%[21] - Net cash flow from investment activities was -¥11,484,015.64, a 38.28% decline compared to -¥8,304,797.49 in the previous year[7] - Cash inflow from financing activities was $53,000,000.00, down from $98,000,000.00 in the prior period, a decline of about 46.0%[22] Operating Expenses and Income - The company reported a significant increase in operating expenses, with a 30.73% decrease in operating costs to ¥33,548,692.35 due to lower revenue[6] - The company reported an operating loss of ¥27,172,651.26, compared to an operating loss of ¥14,982,821.03 in the previous period[19] - The company experienced a 1021.68% increase in income tax expenses, amounting to ¥2,440,975.68, primarily due to profits from its subsidiary[7] - The company reported a 248.57% increase in other operating income to ¥222,926.10, attributed to compensation and penalties received[6] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,003[9] - The largest shareholder, Fujian Aohua Group Co., Ltd., holds 17.00% of shares, totaling 27,068,651 shares, with 20,110,000 shares pledged[9] Research and Development - The company received approval for a Phase II clinical trial of innovative drug GST-HG131 combined with GST-HG141, which will shorten the review and approval cycle[12] - Research and development expenses decreased to ¥6,102,198.78 from ¥7,211,260.72, a reduction of about 15.4% year-over-year[18] Inventory and Assets Changes - The company’s cash and cash equivalents decreased from 143,954,066.36 RMB to 119,506,606.67 RMB, a decline of approximately 16.9%[15] - Inventory increased from 114,475,159.49 RMB to 121,132,863.31 RMB, reflecting a growth of about 5.8%[15] - The company’s long-term equity investments decreased from 80,177,607.81 RMB to 79,100,550.01 RMB, a decline of approximately 1.3%[15] - The company’s total current assets decreased from 407,299,897.31 RMB to 378,047,943.80 RMB, a decline of about 7.2%[15] - The company’s fixed assets decreased from 558,261,569.72 RMB to 545,778,456.17 RMB, a decline of approximately 2.2%[15] - The company’s intangible assets decreased from 251,655,214.92 RMB to 246,276,434.62 RMB, a decline of about 2.1%[15]

证券代码：300436 证券简称：广生堂 公告编号：2025040 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 2025 年 4 月 24 日，福建广生堂药业股份有限公司（以下简称"公司"）创新 药控股子公司福建广生中霖生物科技有限公司（简称"广生中霖"）收到国家药品 监督管理局下发的《药物临床试验批准通知书》，同意 GST-HG131 联合 GST- HG141 用于慢性乙型肝炎的治疗的临床试验。前述联合方案于今年 3 月被纳入 "优化创新药临床试验审评审批试点项目"和此次临床试验申请获得高效批准， 均体现了国家对重大创新药物研发的高度重视和政策支持。公司将积极推动三联 全口服治疗乙肝用药方案，针对核苷（酸）类似物经治乙肝患者，挑战临床治愈 乙肝。 一、《药物临床试验批准通知书》主要内容 1、药品名称： GST-HG141 奈瑞可韦片 申请事项：境内生产药品注册临床试验 受理号和规格： CXHL2500292（25mg）、CXHL2500293（100mg） 申请人：福建广生中霖生物科技有限公司 结论：根据《中华人民共和国药品管理法》及有关规定，经审查， ...

证券代码：300436 证券简称：广生堂 公告编号：2025039 福建广生堂药业股份有限公司 关于 2025 年第一季度报告披露的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特此公告。 福建广生堂药业股份有限公司董事会 2025 年 4 月 24 日 1 福建广生堂药业股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召 开了第五届董事会第九次会议和第五届监事会第八次会议，审议通过了《关于 <2025 年第一季度报告>的议案》。 为使广大投资者全面了解公司 2025 年第一季度的经营成果及财务状况，公 司《2025 年第一季度报告》将于 2025 年 4 月 25 日刊登在中国证券监督管理委 员会指定创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上，敬请投资 者注意查阅。 ...

证券代码：300436 证券简称：广生堂 公告编号：2025035 福建广生堂药业股份有限公司 关于 2025 年第一次临时股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开时间： 1、现场会议召开时间：2025 年 4 月 18 日（星期五）14:00 2、网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 4 月 18 日 9:15—9:25，9:30—11:30 和 13:00—15:00。 （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 4 月 18 日 9:15—15:00。 （二）现场会议召开地点：福建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二期 16 号楼 13F 会议室 （四）会议主持人：董事长李国平先生 （五）会议召开方式：现场表决与网络投票相结合的方式 （六）会议召开的合法、合规性：经公司第五届董 ...

国浩律师（上海）事务所 关 于 福建广生堂药业股份有限公司 2025 年第一次临时股东大会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二零二五年四月 国浩律师（上海）事务所 关于福建广生堂药业股份有限公司 公司向本所律师保证并承诺，公司已将全部事实向本所披露，无任何隐瞒、 遗漏、虚假或误导之处。 本法律意见书仅用于为公司 2025 年第一次临时股东大会见证之目的。本所 律师同意公司将本法律意见书作为本次股东大会的法定文件，随其他文件一并报 送深圳证券交易所审查并予以公告。 本所律师根据《证券法》第一百七十三条的要求，按照律师行业公认的业务 标准、道德规范和勤勉尽责精神，出具法律意见如下： 一、本次股东大会的召集、 ...

Core Viewpoint - Guangshentang (300436) reported a total revenue of 441 million yuan for 2024, reflecting a year-on-year growth of 4.43%, while the net profit attributable to shareholders was -156 million yuan, a significant narrowing of 55.16% compared to the previous year, indicating improved operational quality despite ongoing losses [1][4]. Revenue and Profitability - The company achieved a total revenue of 441 million yuan in 2024, marking a 4.43% increase year-on-year [4]. - The net profit attributable to shareholders was -156 million yuan, showing a substantial reduction of 55.16% year-on-year, although losses persist [4]. - The fourth quarter revenue was 115 million yuan, a decline of 19.5% year-on-year, indicating significant quarterly revenue fluctuations [4]. Impact of Policies and Costs - The ongoing impact of centralized procurement policies has significantly affected profit margins, particularly for hepatitis B products [4]. - Increased intangible assets due to prior construction projects and drug approvals have led to higher depreciation and amortization expenses, further compressing profit margins [4]. Research and Development - Guangshentang has made notable progress in both generic and innovative drug sectors, with five nucleoside analogs for hepatitis B included in the 2024 National Basic Medical Insurance Drug List [5]. - The company’s R&D investment for 2024 was 44.8861 million yuan, a decrease of 85.72% year-on-year, with R&D expenditure accounting for 10.17% of total revenue, down 64.16 percentage points from the previous year [6]. Strategic Partnerships and Shareholder Structure - In November 2024, Guangshentang's controlling shareholder signed a share transfer agreement with a health industry investment fund, enhancing the company's competitiveness in the traditional Chinese medicine sector [7]. - The introduction of strategic investors has optimized the shareholder structure, although total assets and net assets attributable to shareholders decreased by 10.9% and 30.3% respectively compared to the previous year [7].

根据深圳证券交易所发布的《深圳证券交易所股票上市规则(2024 年修订)》及《深圳 证券交易所上市公司自律监管指南第 1 号--业务办理(2024 年修订)》中营业收入扣除事项 的规定，本公司编制 2024 年度营业收入扣除情况明细表以满足监管要求。 具体情况如下: 编制单位：福建广生堂药业股份有限公司 单位：万元 | 项目 | 本年度 | 具体扣除 | 上年度 | 具体扣除情况 | | --- | --- | --- | --- | --- | | | | 情况 | | | | 营业收入金额 | 43,747.98 | | 42,271.49 | | | 营业收入扣除项目合计金额 | 397.78 | | 939.73 | | | 营业收入扣除项目合计金额占营业收入的比重 | 0.90% | | 2.22% | | | 一、与主营业务无关的业务收入 | | | | | | 1．正常经营之外的其他业务收入。如出租固 | | 主要为租 | | | | 定资产、无形资产、包装物，销售材料，用材 | | 赁收入， | | 主要为租赁收 | | 料进行非货币性资产交换，经营受托管理业务 | 397.78 | | 28 ...